Recent developments include a $10 million standby equity facility, significant growth in sales and gross profit reported in Q3 2025, and a listing on the OTCID market with plans for OTCQB.

• CirTran Corporation announced a $10 million standby equity facility in December 2025 [N1].
• The company reported 75% growth in sales and 41% growth in gross profit in its third-quarter 2025 Form 10-Q filing [N2].
• CirTran Corporation announced its listing on the OTCID market in August 2025 and indicated intentions to move to the higher-tier OTCQB market [N3].
• Earlier filings reported growth in sales and gross profit in 2022 and 2021, with notable increases in net sales and gross margins [N4][N5][N6].
• CirTran reported net profit for 2020 in its Form 10-K filing [N7].
• The company manufactures and distributes HUSTLER®-licensed adult lifestyle and entertainment products through its subsidiary LBC Products [N8].

CirTran has demonstrated significant sales and gross profit growth in recent periods, supported by its exclusive licensing agreements and expanding product portfolio. Its global manufacturing partnerships and turnkey service offerings position it to capitalize on outsourcing trends in manufacturing. The $10 million standby equity facility announced in late 2025 provides additional capital resources to support operations and growth initiatives.

Despite revenue growth, CirTran continues to report net losses and faces liquidity challenges, with a current ratio well below 1. The company operates with a small full-time workforce and relies heavily on contract workers and consultants, which may impact operational scalability. Competition from larger firms and customers' internal manufacturing capabilities pose risks. Regulatory compliance and dependency on licensing agreements also present potential vulnerabilities.

CirTran's moat is primarily based on its exclusive manufacturing and distribution agreement for HUSTLER®-branded products and its established relationships with global manufacturing suppliers. Its ability to provide turnkey contract manufacturing services, including design, engineering, and distribution, offers value to customers seeking to outsource production. However, the company faces competition from larger manufacturers and potential internal manufacturing by customers, limiting its competitive barriers.

• Liquidity Risk: As of December 31, 2025, CirTran had a current ratio of 0.09 and a cash ratio of 0.01, indicating significant liquidity constraints that may affect its ability to meet short-term obligations.
• Operating Losses: The company has a history of operating losses and an accumulated deficit of approximately $61.8 million as of March 31, 2025, which may impact its financial stability.
• Competitive Pressure: CirTran faces competition from larger manufacturers with greater resources and from customers who may choose to manufacture products internally, which could limit growth opportunities.
• Regulatory Compliance: The company must comply with various federal, state, and local regulations, including FDA certifications and tobacco product licensing, which could impose operational constraints or costs.
• Dependency on Licensing Agreements: CirTran's business relies on exclusive licensing agreements, such as with GloBrands for the HUSTLER® brand, which are subject to termination or modification by licensors.

• CirTran Corporation operates through three subsidiaries: LBC Products, Inc., CirTran Products Corp., and CirTran - Asia, Inc.
• The company manufactures, markets, and distributes a variety of consumer products including tobacco products, medical devices, beverages, and licensed adult lifestyle products under the HUSTLER® brand.
• CirTran has an exclusive manufacturing and distribution agreement with GloBrands, LLC for HUSTLER®-branded products including condoms, electronic cigarettes/cigars, cigars, hookahs, hookah tobacco, energy drinks, water beverages, and related merchandise.
• The HUSTLER® brand is licensed from the Flynt/HUSTLER® organization, which operates various adult entertainment venues and retail stores globally.
• CirTran focuses on contract manufacturing and marketing relationships primarily in domestic consumer product markets such as home and garden, kitchen, health and beauty, toys, and licensed merchandise for entertainment and sports franchises.
• The company provides full product development services from design, engineering, prototyping, manufacturing, packaging, marketing, inventory control, distribution, shipping, warranty fulfillment, and customer service.
• CirTran has manufacturing relationships with foreign and domestic suppliers, leveraging offshore contract manufacturing in countries including China, Hungary, The Netherlands, South Africa, and India.
• The company recognizes revenue from product design services and sales of tangible products, with revenues recognized upon transfer of control to customers.
• As of December 31, 2025, CirTran had four full-time employees and 23 part-time contract workers, relying heavily on contractors and consultants.
• CirTran reported net sales growth and gross profit increases in recent years, including 75% growth in sales and 41% growth in gross profit in Q3 2025.
• The company announced a $10 million standby equity facility in December 2025.
• CirTran's financials as of December 31, 2025, show a net loss of $701,634 and basic and diluted EPS of -$0.14.
• As of December 31, 2025, CirTran had current assets of approximately $2.26 million and current liabilities of approximately $24.69 million, resulting in a current ratio of 0.09 and a cash ratio of 0.01, indicating liquidity challenges.
• The company has convertible debentures and notes payable, including a secured convertible debenture with Tekfine, LLC, with maturity dates through 2027.
• CirTran's accumulated deficit was approximately $61.8 million as of March 31, 2025.
• The company has a history of losses from operations, with expenses exceeding revenues.
• CirTran's contract manufacturing business model emphasizes turnkey manufacturing services, including design, engineering, procurement, testing, and distribution, often using just-in-time inventory management.
• The company faces competition from larger firms with greater resources and from customers who may choose to manufacture internally.
• CirTran complies with applicable regulations including FDA 510(k) certification for medical devices and tobacco product licensing.
• Marketing costs are reimbursed by the entity licensing the products, with negligible expenses attributed to CirTran itself.